secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intra-Cellular Therapies, Inc. (—)
CIK:        0001567514
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001193125-24-100960
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intra-Cellular Therapies prices $500M public offering of 6.85M shares at $73.00 per share
--------------------------------------------------------------------------------

- Gross proceeds of $500M from 6,849,316 shares at $73.00/share; net proceeds ~$472.1M after underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to 1,027,397 additional shares on same terms.
- Offering expected to close April 22, 2024; J.P. Morgan, Leerink, BofA, Morgan Stanley, RBC acting as joint book-runners.
- Company is selling all shares; no specific use of proceeds disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/0001193125-24-100960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/d816580d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-100960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer